Legal developments in real estate acquisition and land rights in Uzbekistan in the pharmaceuticals sector

Foreign pharmaceutical companies acquiring operational footholds in Uzbekistan — through manufacturing facilities, distribution warehouses, or research and development sites — are navigating a land and property regime that has shifted materially in recent years. Uzbekistan's broader legal modernisation programme has produced a series of reforms to land-use rights, property registration procedures, and the conditions under which foreign-owned legal entities may secure long-term rights over industrial and commercial land. For in-house counsel and market-entry advisers assessing the feasibility of a pharmaceutical manufacturing or distribution presence in the country, understanding how these changes interact with sector-specific licensing requirements is now an essential threshold question.

Uzbekistan operates a land system in which the state retains ultimate ownership of all land. Foreign legal entities and foreign-invested enterprises established under Uzbek law may not acquire freehold title to land; they may, however, obtain long-term lease rights — commonly described as the right of use or right of lease — over plots designated for industrial, commercial, or pharmaceutical production purposes. This foundational rule has not changed, but the procedural, documentary, and zoning framework around it has been revised in ways that matter significantly for pharmaceutical sector investors.

The principal changes cluster around three areas. First, the digitalisation of the State Cadastre has improved the speed and transparency of land plot identification and lease registration, but has also introduced new documentary requirements that foreign-invested enterprises occasionally encounter without preparation. Plots must now be identified against updated cadastral records, and discrepancies between legacy survey data and current digital records can delay lease formalisation. Second, the designation categories for land allocated to pharmaceutical production or storage have been clarified. Investors establishing Good Manufacturing Practice-compliant production facilities — a requirement for virtually all foreign pharmaceutical manufacturers operating in Uzbekistan's regulated market — must verify that the plot's designated land-use category expressly permits pharmaceutical industrial activity; a general industrial designation may not suffice without reclassification approval. Third, the conditions attaching to leases granted to enterprises registered in special economic zones and pharmaceutical clusters have been updated, with some zones now offering extended lease terms and reduced ground-rent rates in exchange for investment volume and employment commitments.

The overall direction of reform is favourable to foreign pharmaceutical investors, but the gap between the legislative intention and the day-to-day procedural reality at the district administration and cadastral authority level remains a practical constraint that investors underestimate at their cost.

The changes described above affect any foreign company — whether investing independently, through a joint venture with an Uzbek partner, or through a subsidiary established under Uzbek law — that intends to operate from a fixed physical site in Uzbekistan. Within that population, pharmaceutical companies face a distinctive set of overlapping regulatory requirements that make the real estate question more complex than for a general manufacturer or distribution business.

A pharmaceutical enterprise in Uzbekistan must satisfy the Agency for the Development of the Pharmaceutical Industry (or its successors, as the regulatory architecture has been subject to periodic reorganisation) as to both its legal establishment and its physical premises before it may obtain the manufacturing licences or product registration approvals that allow it to operate commercially. The premises used for production or quality-controlled storage must meet GMP standards; those standards impose requirements on building construction, clean-room separation, HVAC systems, and utilities that are materially more demanding than generic industrial specifications. An investor acquiring a lease over an existing industrial plot in order to construct a GMP-compliant facility must therefore assess, at the land-rights stage, whether the plot's zoning, utilities connectivity, and spatial dimensions are compatible with the facility specification — not merely whether a lease can be obtained in principle.

For foreign companies that have previously operated pharmaceutical distribution or manufacturing businesses in Russia or elsewhere in the CIS, the Uzbek framework presents some conceptual familiarity — state land ownership, lease-based rights for foreign-invested enterprises, cadastral registration requirements — but the institutional actors, the procedural sequences, and the specific sector overlays are materially different. Cross-border experience from the Russian or Kazakhstani markets, while useful background, does not substitute for specific Uzbek legal advice on the current regulatory position.

[CTA: If your company is assessing a pharmaceutical manufacturing or distribution site in Uzbekistan and needs clarity on land-use rights and sector licensing — make an enquiry: info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76]

The practical implications of the current regulatory position can be grouped into three areas of immediate relevance for foreign in-house counsel and their advisers.

First, conduct land-use due diligence before any site commitment. The enthusiasm for a particular plot — because of its location, proximity to transport infrastructure, or existing building stock — should not cause an investor to defer the land-use classification analysis. An independent review of the plot's cadastral record, designated land-use category, and any encumbrances or restrictions registered against it should be completed before heads of terms are agreed, not after. Reclassification of land-use categories in Uzbekistan is possible but involves engagement with local authority planning bodies and the relevant state committees, and the timeline is not guaranteed.

Second, structure the investment entity in light of the land-access rules, not separately from them. The type of legal entity through which the investor intends to operate in Uzbekistan — a wholly foreign-owned limited liability company, a joint venture with an Uzbek participant, or an enterprise registered within a special economic zone — affects both its eligibility for different categories of lease and the procedural route to obtaining that lease. Investors who form their Uzbek entity and then discover that the entity type selected does not optimise access to the preferred land plot category create unnecessary restructuring costs. Entity formation and land-access planning should proceed in parallel.

Third, map the pharmaceutical licensing timeline against the property registration sequence. The two processes — obtaining a pharmaceutical manufacturing or import licence and securing a registered lease over the operating premises — involve different authorities and different timelines, but each depends on the other. Pharmaceutical regulators in Uzbekistan will typically require evidence of secured and compliant premises as part of the licensing application; those premises must be identified, leased, and at least provisionally registered before that evidence can be produced. A project plan that treats these as sequential rather than parallel workstreams is almost always longer and more expensive than necessary.

Investors with existing operations in the Russian market who are expanding into Uzbekistan as part of a regional diversification strategy should be alert to the fact that Uzbekistan is not an EAEU member state. Market access terms, regulatory mutual recognition arrangements, and product registration pathways that operate within the EAEU single market do not extend automatically to Uzbekistan. Each element of the market-entry structure must be assessed against Uzbek law independently.

[CTA: For in-house counsel managing a pharmaceutical market-entry programme in Uzbekistan — request our practice review: info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76]

Several areas of the current regulatory framework remain in active development and introduce uncertainty for investors planning on a medium or long horizon.

The regulatory architecture governing pharmaceutical industry oversight in Uzbekistan has been subject to institutional reorganisation in recent years. The allocation of functions between the Ministry of Health, the agency responsible for pharmaceutical industry development, and the bodies responsible for product registration and quality control is not always clear from legislation alone; the practical division of competence between these bodies at the level of individual licensing decisions and premises inspections is better understood through engagement with current practitioners in the market than through a reading of the formal legal texts.

The interaction between special economic zone benefits and general pharmaceutical licensing requirements is a second area of open interpretation. Companies establishing within designated pharmaceutical clusters or free economic zones may be eligible for preferential lease terms, reduced duties on imported equipment, and expedited licensing procedures. However, the conditions attaching to those benefits — including investment volume thresholds, employment commitments, and local content requirements — are subject to revision by zone administration authorities, and what was agreed at the point of entry may be renegotiated or supplemented over the life of an investment.

Finally, the question of land-use rights upon liquidation or transfer of a foreign-invested enterprise remains an area where the rules are clear in principle — the state recovers the land — but the practical consequences for an investor seeking to exit through a sale of its Uzbek operating company require careful transactional structuring. The purchaser of an Uzbek enterprise operating from leased state land must obtain a transfer or novation of the lease, a process that involves the relevant state land authority and that is not guaranteed to proceed on the timeline or terms that a share sale transaction would otherwise contemplate.

• [Market entry and company formation in Uzbekistan for foreign investors](/jurisdictions/uzbekistan/company-formation/)
• [Regulatory and licensing requirements for pharmaceutical companies in Uzbekistan](/jurisdictions/uzbekistan/regulatory-licensing/)
• [Corporate structures and joint ventures in Uzbekistan: a guide for foreign companies](/jurisdictions/uzbekistan/corporate-jv/)

Q: What has specifically changed in Uzbekistan's land and property framework that affects pharmaceutical investors?

A: The principal recent developments are the digitalisation of the State Cadastre, which has updated documentary requirements for lease registration; the clarification of land-use designation categories applicable to pharmaceutical production and storage; and revisions to the lease terms and incentives available to enterprises operating within designated pharmaceutical clusters and special economic zones. These changes collectively make the upfront land-use classification analysis more consequential: a plot that carries only a general industrial designation may require reclassification before it can be used for GMP-compliant pharmaceutical manufacturing, and that reclassification process involves engagement with local planning bodies over a timeline that is difficult to predict with precision.

Q: Which types of foreign pharmaceutical company are most directly affected by these developments?

A: The changes are most directly relevant to foreign pharmaceutical manufacturers and importers seeking to establish a physical production or quality-controlled storage presence in Uzbekistan — whether through a wholly foreign-owned subsidiary, a joint venture with an Uzbek partner, or an enterprise registered within a special economic zone. Companies operating exclusively through a distribution arrangement with an Uzbek distributor — without direct control over premises — are less immediately affected, though the premises compliance requirements that apply to their Uzbek distribution partners are subject to the same framework. Foreign companies with existing operations in Russia or other CIS markets who are entering Uzbekistan as a distinct regulatory jurisdiction for the first time face the additional consideration that EAEU market-access arrangements do not extend to Uzbekistan.

Q: What should foreign pharmaceutical companies do in the near term given these developments?

A: Three steps are advisable before any site commitment is made: verify the land-use classification of any candidate plot against current cadastral records; assess whether the legal entity through which the investor proposes to operate in Uzbekistan optimises its access to the relevant category of lease; and map the pharmaceutical licensing timeline against the property registration process to identify dependencies and avoid sequential delays. Companies at an earlier stage of market assessment should obtain current legal advice specifically addressing the Uzbek position — including the current state of the regulatory architecture governing pharmaceutical licensing — rather than extrapolating from their experience in other regional markets.

Vetrov & Partners is a Russian boutique law firm established in 2009, recognised by Pravo-300 for eight consecutive years and listed as a trusted adviser by the German Consulate General in Novosibirsk. The firm's Uzbekistan coverage is provided in collaboration with regional counsel and contributing analysts with current market experience.

For foreign pharmaceutical companies and their advisers assessing investment structures, land-use rights, and regulatory pathways in Uzbekistan, the firm offers structured practice reviews drawing on both Russian-law expertise and regional cross-border experience. With over 1,000 matters handled since inception, the team provides direct partner involvement and English-language advice throughout.

Enquiries: info@vetrovpartners.com | WhatsApp / Telegram: +7 (983) 510-38-76 | t.me/vitvetcom

[CTA: Make an enquiry — info@vetrovpartners.com | WhatsApp/Telegram: +7 (983) 510-38-76]

This publication is provided for informational purposes only and does not constitute legal advice under Russian or any other applicable law. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Vetrov & Partners is a Russian-qualified law firm. For matters governed by foreign law or requiring local admission in another jurisdiction, we collaborate with trusted counsel in the relevant jurisdiction. For advice regarding your particular situation, please contact info@vetrovpartners.com.

— Nodira Yusupova Contributing Regional Analyst — Uzbekistan, Vetrov & Partners vetrovpartners.com/contributions/